Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT by DeFilipp, Z. et al.
This is an author produced version of Metabolic Syndrome and Cardiovascular Disease 
after Hematopoietic Cell Transplantation: Screening and Preventive Practice 
Recommendations from the CIBMTR and EBMT.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/103719/
Article:
DeFilipp, Z., Duarte, R.F., Snowden, J.A. et al. (34 more authors) (2016) Metabolic 
Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: 
Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. 
Biology of Blood and Marrow Transplantation, 22 (8). pp. 1493-1503. ISSN 1083-8791 
https://doi.org/10.1016/j.bbmt.2016.05.007
Article available under the terms of the CC-BY-NC-ND licence 
(https://creativecommons.org/licenses/by-nc-nd/4.0/)
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
 1 
 1 
Metabolic syndrome and cardiovascular disease following hematopoietic cell 2 
transplantation: screening and preventive practice 3 
recommendations from CIBMTR and EBMT  4 
 5 
 6 
  7 
Zachariah DeFilipp1; Rafael F. Duarte2; John A. Snowden3; Navneet S. Majhail4; 8 
Diana M. Greenfield5; José López Miranda6; Mutlu Arat7; K. Scott Baker8; Linda 9 
J. Burns9; Christine N. Duncan10; Maria Gilleece11; Gregory A. Hale12; Mehdi 10 
Hamadani13; Betty K. Hamilton4; William J. Hogan14; Jack W. Hsu15; Yoshihiro 11 
Inamoto16; Rammurti T. Kamble17; Maria Teresa Lupo-Stanghellini18; Adriana K. 12 
Malone19; Philip McCarthy20; Mohamad Mohty21-23; Maxim Norkin15; Pamela 13 
Paplham20; Muthalagu Ramanathan24; John M. Richart25; Nina Salooja26; Harry 14 
C. Schouten27; Helene Schoemans28; Adriana Seber29,30; Amir Steinberg19; 15 
Baldeep M. Wirk31; William A. Wood32; Minoo Battiwalla33; Mary E.D. Flowers8; 16 
Bipin N. Savani34; Bronwen E. Shaw13 17 
 18 
1Department of Hematology and Medical Oncology, Winship Cancer Institute of 19 
Emory University, Atlanta, GA; 2Hospital Universitario Puerta de Hierro 20 
Majadahonda, Madrid, Spain; 3Department of Haematology, Sheffield Teaching 21 
Hospitals NHS Foundation Trust and Department of Oncology & Metabolism, 22 
University of Sheffield, Sheffield, UK; 4Department of Hematology and Oncology, 23 
Cleveland Clinic, Cleveland, OH; 5Specialized Cancer Services, Sheffield 24 
Teaching Hospital NHS Foundation Trust, Shefflied, UK; 6Department of 25 
Medicine, Reina Sofia University Hospital, Maimonides Institute for Biomedical 26 
Research at Cordoba (IMIBIC), University of Cordoba, CIBER Fisiopatología 27 
Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Spain; 7Florence 28 
Nightingale Sisli Hospital, Hematopoietic Stem Cell Transplantation Unit, 29 
Istanbul, Turkey; 8Clinical Research Division, Fred Hutchinson Cancer Research 30 
Center, Seattle, WA; 9National Marrow Donor Program, University of Minnesota, 31 
Minneapolis, Minnesota; 10Pediatric Stem Cell Transplant, Dana-Farber Cancer 32 
Institute, Boston, MA; 11Leeds Teaching Hospitals NHS Trust, Leeds, UK; 12All 33 
&KLOGUHQ¶V +RVSLWDO -RKQ +RSNLQV 0HGLFLQH 6W 3HWHUVEXUJ )/ 13Center for 34 
International Blood and Marrow Transplant Research (CIBMTR®), Department of 35 
Medicine, Medical College of Wisconsin, Milwaukee, WI; 14Division of 36 
Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, 37 
Minnesota; 15Division of Hematology & Oncology, Department of Medicine, 38 
University of Florida, Gainesville, FL; 16Division of Hematopoietic Stem Cell 39 
Transplantation, National Cancer Center Hospital, Tokyo, Japan; 17Division of 40 
Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of 41 
Medicine, Houston, TX; 18Hematology and Bone Marrow Transplantation Unit, 42 
San Raffaele Scientific Institute, Milano, Italy; 19Division of 43 
Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount 44 
Sinai, New York, NY; 20Roswell Park Cancer Institute, BMT Program, 45 
Department of Medicine, Buffalo, NY; 21University Pierre & Marie Curie, Paris, 46 
 2 
France; 22Hopital Saint-Antoine, AP-HP, Paris, France; 23INSERM UMRs 938, 47 
Paris, France; 24Department Hematology, Oncology and Bone Marrow 48 
Transplant, UMass Memorial Medical Center, Worcester, MA; 25Saint Louis 49 
University, Department of Internal Medicine, Division of Hematology and Medical 50 
Oncology, St. Louis, Missouri; 26Hammersmith Hospital, London, UK; 51 
27Maastricht University Medical Center, the Netherlands; 28Department of 52 
Hematology, University Hospital Leuven and KU Leuven, Leuven, Belgium; 53 
29Hospital Samaritano, Sao Paulo, Brazil; 30Associação da Medula Ossea - 54 
AMEO, Sao Paulo, Brazil; 31Department of Internal Medicine, Stony Brook 55 
University Medical Center, Stony Brook, NY; 32Division of Hematology/Oncology, 56 
Department of Medicine, University of North Carolina, Chapel Hill, Chapel Hill, 57 
NC; 33Hematology Branch, National Institutes of Health, Bethesda, MD; 34Division 58 
of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical 59 
Center, Nashville, Tennessee 60 
 61 
Short Title:  MetS and cardiovascular disease following HCT 62 
 63 
 64 
Corresponding Author: Bronwen Shaw, MD PhD 65 
    Department of Medicine 66 
Center for International Blood and Marrow Transplant 67 
Research 68 
Medical College of Wisconsin 69 
9200 W Wisconsin Ave 70 
Milwaukee, WI 53226 71 
Phone: 414-805-0700 72 
Fax: 414-805-0714 73 
Email: beshaw@mcw.edu 74 
 75 
Abstract Word Count: 177 76 
Manuscript Word Count: 4517 77 
Tables:   3 78 
Figure:   0 79 
 80 
Financial Disclosure: The authors have no financial interests to disclose. 81 
 3 
Abstract 82 
 83 
Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that 84 
increases the risk of cardiovascular disease, diabetes mellitus, and all cause 85 
mortality. Long-term survivors of hematopoietic stem cell transplantation (HCT) 86 
have a substantial risk of developing MetS and cardiovascular disease, with the 87 
estimated prevalence of MetS being 31-49% amongst HCT recipients. While 88 
MetS has not yet been proven to impact cardiovascular risk after HCT, an 89 
understanding of the incidence and risk factors for MetS in HCT recipients can 90 
provide the foundation to evaluate screening guidelines and develop 91 
interventions that may mitigate cardiovascular-related mortality. A working group 92 
was established through the Center for International Blood and Marrow 93 
Transplant Research and the European Group for Blood and Marrow 94 
Transplantation with the goal to review literature and recommend practices 95 
appropriate to HCT recipients. Here we deliver consensus recommendations to 96 
help clinicians provide screening and preventive care for MetS and 97 
cardiovascular disease among HCT recipients. All HCT survivors should be 98 
advised of the risks of MetS and encouraged to undergo recommended 99 
screening based on their predisposition and ongoing risk factors. 100 
  101 
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 103 
Introduction 104 
Advances in hematopoietic cell transplantation (HCT) and supportive care have 105 
led to substantial improvements in transplant outcomes and an increased 106 
number of long-term HCT survivors [1]. Transplant survivors are at considerable 107 
risk for developing significant late effects and experience mortality rates higher 108 
than the general population [2, 3]. One challenge faced in the post-HCT setting is 109 
the development of metabolic syndrome (MetS), with reported prevalence rates 110 
of 31-49% [4-8]. HCT recipients are predisposed to develop MetS through 111 
several mechanisms, including conditioning regimen-mediated damage to the 112 
neurohormonal system and vascular endothelium, as well as the immunological 113 
and inflammatory effects of allografting (including subsequent graft-versus-host 114 
disease (GVHD) and its therapy) [4]. Individuals in the general population with 115 
MetS are twice as likely to develop cardiovascular disease than those without 116 
MetS [9]. A better understanding of MetS following HCT may prove to be 117 
significant, as HCT survivors are known to be at increased risk for cardiovascular 118 
morbidity and mortality. In the Bone Marrow Transplant Survivor Study (BMTSS), 119 
the risk of premature cardiovascular-related death following HCT was found to be 120 
increased 2.3-fold compared to the general population [2, 3]. Similarly, others 121 
have reported the risk of cardiovascular hospitalizations and mortality to be 122 
increased by 3.6-fold in HCT recipients compared to the general popuation [10]. 123 
 124 
Intensive chemotherapy and radiation have been associated with MetS and 125 
contribute to the development of this syndrome post-HCT, especially in heavily 126 
pre-treated populations [11, 12]. MetS has not yet been proven to impact 127 
cardiovascular risk after HCT. However, an understanding of the incidence and 128 
risk factors for MetS and cardiovascular disease following HCT provide the 129 
foundation to evaluate screening guidelines and develop interventions that may 130 
mitigate cardiovascular-related mortality. Therefore, a collaboration was 131 
established between the Center for International Blood and Marrow Transplant 132 
Research (CIBMTR) Late Effects and Quality of Life Working Committee and the 133 
European Group for Blood and Marrow Transplantation (EBMT) Complications 134 
and Quality of Life Working Party with the goal to review literature, including 135 
previously published guidelines for screening and preventive practices for HCT 136 
survivors [13-15]. We subsequently provide specific screening and preventive 137 
practice recommendations for MetS and cardiovascular disease appropriate to 138 
HCT recipients based on published evidence and expert opinion.  139 
 140 
Metabolic syndrome 141 
MetS is a cluster of interrelated factors that increases the risk of cardiovascular 142 
disease, diabetes mellitus (DM), and all cause mortality [16-18]. The International 143 
Diabetes Foundation (IDF) estimates that 25% RIWKHZRUOG¶VDGXOWSRSXODWLRQKDV144 
MetS [19]. The four core clinical measures are increased body weight/visceral 145 
adiposity, elevated lipids, raised blood pressure (BP), and hyperglycemia/insulin 146 
resistance (IR) [20]. The individual diagnostic criteria of MetS have varied over 147 
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time according to the different definitions applied. The diagnostic criteria of the 148 
National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) 149 
[21], the IDF [22], the American Heart Association (AHA) [9] and the World 150 
Health Organization (WHO) [23] are shown in Table 1. A comparison of various 151 
definitions in terms of their predictive value established that the prevalence of 152 
MetS was significantly greater when using the criteria of the AHA and IDF 153 
compared with the NCEP ATPIII definition [24]. However, the risks of 154 
cardiovascular events and death were markedly greater for participants who 155 
satisfied any of the criteria for diagnosis of MetS compared with healthy 156 
individuals. This supports other reports that found agreement between MetS 157 
components and cardiovascular risk factors in the general population [25, 26].  158 
 159 
Abdominal obesity 160 
Obesity, defined as a body mass index (BMI) 30 kg/m2, affects 35% of adults in 161 
the United States [27] and 10-30% of adults in Europe [28]. Obese persons have 162 
a higher risk of developing serious medical conditions, including hypertension 163 
(HTN), dyslipidemia, type 2 DM, coronary heart disease (CHD), and ischemic 164 
stroke, and have a higher mortality than the non-obese population [29]. However, 165 
BMI is an insufficient measure of abdominal obesity. Waist circumference, which 166 
emphasizes visceral adipose deposits, is preferentially used in the evaluation of 167 
abdominal obesity when defining MetS (see Table 1) as this distribution of fat 168 
accumulation independently confers cardiometabolic risk [30, 31]. Yet, as studies 169 
reporting waist circumference at the time of and following HCT are limited, BMI 170 
may act as a possible surrogate.  171 
 172 
BMI 35 kg/m2 (severely obese) is part of the HCT-specific Comorbidity Index 173 
since 2005, as this was determined to be a risk factor for increased non-relapse 174 
mortality (NRM) [32-35]. While pre-transplant obesity can influence body 175 
composition following HCT, changes in waist circumference can be seen 176 
independent of pre-existing obesity. Despite what may be a normal BMI, HCT 177 
survivors are at an increased risk to develop sarcopenic obesity (increase in 178 
percent fat mass, decrease in lean body mass), which can significantly contribute 179 
to IR [36, 37]. A longitudinal study using dual X-ray absorptiometry (DXA) to 180 
calculate body fat mass index (BFMI) in 82 patients found the prevalence of a 181 
high BFMI was greater at 2-3 years following allo-HCT than in healthy controls 182 
[38]. Corticosteroids, which remain the first line treatment of GVHD, contribute to 183 
sarcopenic obesity by promoting muscle atrophy and may contribute to obesity in 184 
the early post-HCT period [39, 40]. Robust data on the changes in abdominal 185 
obesity following autologous HCT (auto-HCT) are lacking. One study evaluated 186 
metabolic and body composition changes in 32 patients with multiple myeloma 187 
who had received three lines of intensive treatment, including at least one HCT. 188 
At a median duration of 6 years from diagnosis, DXA identified sarcopenic 189 
obesity in 65% of patients [41]. Importantly, the development of sarcopenic 190 
obesity following HCT has yet to be independently associated with increased 191 
cardiovascular mortality. In the pediatric population, a cross-sectional study 192 
evaluating 54 allo-HCT survivors and 894 healthy participants found a deficiency 193 
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in lean mass (as identified by DXA) as compared to fat mass in HCT survivors 194 
[42]. A prospective, descriptive, cross-sectional study evaluating children and 195 
adolescents for the development of MetS post-HCT found that 73% of individuals 196 
with this diagnosis had a characteristic of abdominal obesity (abdominal 197 
circumference >75th percentile by age and gender) [5]. 198 
 199 
Screening and preventive recommendations  200 
The United States Preventive Services Task Force (USPSTF) and the National 201 
Heart, Lung, Blood Institute (NHLBI) recommend screening for obesity in all 202 
adults and children >2 years of age, though no recommendation is made 203 
regarding appropriate intervals for screening. Current guidelines for HCT 204 
recipients do not provide specific screening recommendations for abdominal 205 
obesity, though education and counseling regarding regular exercise, healthy 206 
weight, and dietary counseling are encouraged [14, 15]. Given the increase in 207 
abdominal obesity that can occur after HCT, clinicians should consider 208 
monitoring body composition at each visit, with regular measurement of height, 209 
weight, and waist circumference (at least yearly). Based on what is known in 210 
other populations, we recommend that patients with a %0,  NJP2, waist 211 
circumference >102 cm (>40 inches) in men or >88 cm (>35 inches) in women, 212 
or significant increases in either of these measurements should be considered for 213 
intensive, multicomponent behavioral interventions. DXA may be used to assist 214 
evaluation and monitoring of changes in body composition in survivors of HCT.  215 
 216 
Dyslipidemia 217 
Dyslipidemia, defined as elevated levels of total cholesterol, low-density 218 
lipoprotein (LDL) cholesterol or triglycerides, or low levels of high-density 219 
lipoprotein (HDL) cholesterol, is an important risk factor for CHD and ischemic 220 
stroke [43, 44]. The prevalence of dyslipidemia is high in the general population: 221 
in 2000, approximately 25% of adults in the United States had total cholesterol 222 
greater than  mg/dL ( mmol/L) or were taking lipid-lowering medication 223 
[45]. A high prevalence of dyslipidemia has also been reported in European 224 
countries [46, 47]. Of the various dyslipidemias, low HDL (<40-50 mg/dL, <1.0-225 
1.3 mmol/L) and hypertriglyceridemia (>150 mg/dL, >1.7 mmol/L) have been 226 
incorporated into the diagnostic criteria of MetS (see Table 1).  227 
 228 
Survivors of allo-HCT are at an increased risk of post-transplant dyslipidemia. In 229 
a retrospective cohort study comparing incidence and risk factors for 230 
cardiovascular events, allo-HCT recipients had significantly higher risk of new-231 
onset dyslipidemia (RR: 2.31; 95% CI, 1.15 to 4.65) compared to auto-HCT 232 
recipients [48]. Single institution studies have estimated the incidence of 233 
hypercholesterolemia and/or hypertriglyceridemia following allo-HCT to be 43-234 
73% [49, 50]. The onset of dyslipidemia post-HCT can be rapid, with the median 235 
interval to development of hypertriglyceridemia and hypercholesterolemia being 8 236 
and 11 months following allo-HCT, respectively, in one single center experience 237 
[49]. Factors predicting development of post-HCT dyslipidemia include family 238 
history of hyperlipidemia, obesity, high-dose total body irradiation (TBI), grade II-239 
 7 
IV acute GVHD, chronic GVHD, and chronic liver disease [5, 8, 49-51]. In 240 
addition, immunosuppressant medications (e.g., sirolimus, calcineurin inhibitors, 241 
corticosteroids) not only increase lipid levels but also lead to significant drug-drug 242 
interactions with 3-hydroxy-3-methyl-gutaryl (HMG)-CoA reductase inhibitors 243 
(statins) via the cytochrome p450 pathway [52, 53]. Data regarding the incidence 244 
of dyslipidemia following auto-HCT are limited. In a single center analysis 245 
evaluating late post-HCT cardiovascular complications in 1379 patients, which 246 
included both auto- and allo-HCT recipients, 1-year post-HCT dyslipidemia 247 
requiring treatment was associated with an increased risk for stroke (HR 7.4; 248 
95% CI, 1.2-47) [54]. In the pediatric population, the risk of hypercholesterolemia 249 
is high in childhood cancer survivors who underwent auto-HCT (HR = 3.2; CI 1.7-250 
5.9) [55].   251 
 252 
Screening and preventive recommendations 253 
The USPSTF strongly recommends screening for lipid disorders every 5 years in 254 
PHQ\HDUVZRPHQ\HDUVDQGSHUVRQV\HDUVDW LQFUHDVHG risk for 255 
CHD, while the NHLBI recommends screening in children between the ages of 9-256 
11 years or earlier in those with family history. Current guidelines for HCT 257 
recipients recommend similar screening practice for dyslipidemia amongst the 258 
general population [14, 15]. We recommend standard-risk patients (including 259 
auto-HCT recipients without personal risk factors) should follow these guidelines.  260 
However, early onset of dyslipidemia following allo-HCT is not uncommon, 261 
especially in high-risk patients. Thus, we propose early assessment of exposures 262 
and risk factors in all HCT patients. For recipients of allo-HCT, we suggest an 263 
initial lipid profile 3 months after HCT. For high-risk patients with ongoing risk 264 
factors (including those on sirolimus, calcineurin inhibitors, corticosteroids), we 265 
suggest repeat evaluation every 3-6 months. Non-pharmacologic management of 266 
dyslipidemia primarily involves lifestyle modifications such as diet (low saturated 267 
fat and low cholesterol), exercise (or other regular physical activities), weight 268 
reduction, smoking cessation, and limiting alcohol intake. Although not validated 269 
amongst HCT survivors, we recommend use of the Framingham risk score 270 
(http://cvdrisk.nhlbi.nih.gov) to assess cardiovascular risk and guide therapy 271 
decisions [43]. The safety of lipid-lowering agents must be considered in the 272 
pediatric population, as the AHA recommends considering drug therapy for high-273 
risk lipid abnormalities LQ ER\V  \HDUV RI DJH DQG DIWHU RQVHW RI PHQVHV LQ274 
girls, preferably after a 6 to 12 month trial of saturated fat- and cholesterol-275 
restricted dietary management [56]. 276 
 277 
Hypertension 278 
HTN, defined as a systolic BP 140 mmHg or diastolic BP 90 mmHg, is a 279 
worldwide epidemic affecting approximately ~25% of adults [57]. Of note, the 280 
blood pressure criteria used in most definitions of MetS is systolic BP 135 281 
mmHg or diastolic BP 85 mmHg (or drug treatment for HTN) (see Table 1), 282 
which is classified as pre-hypertension according to the report from the Eighth 283 
Joint National Committee (JNC 8) [58]. 284 
 285 
 8 
An analysis of the BMTSS showed that after adjustment for age, sex, race, and 286 
BMI, allo-HCT recipient were 2.06 times (95% CI, 1.39-3.04) more likely to report 287 
HTN as compared to sibling donors or auto-HCT recipients, who had a similar 288 
risk (OR, 0.96; 95% CI, 0.65-1.44) [59]. Similarly, a retrospective, single-289 
institution evaluation of 265 long-term transplant survivors reported that allo-HCT 290 
recipients have an increased risk of HTN (RR: 2.50; 95% CI, 1.19 to 5.27) 291 
compared to auto-HCT patients [48]. A direct cause and effect relationship of 292 
conditioning regimen, acute or chronic GVHD and HTN was not established [59]. 293 
Two large retrospective studies did not show a significant difference in the 294 
incidence of HTN in allo-HCT recipients with or without GVHD [59, 60]. It appears 295 
that HTN is related to use of certain GVHD therapies (e.g., calcineurin inhibitors, 296 
steroids) rather than GVHD induced pro-inflammatory cytokine response and 297 
endothelial damage. Although pediatric patients are less likely than adults to 298 
have pre-transplant HTN as well as any risk factors for HTN, an analysis of 1-299 
year survivors of allo-HCT found a similar incidence of post-HCT HTN in adult 300 
(68%) and pediatric (73%) HCT survivors [61]. In multivariate analyses, exposure 301 
to cyclosporine increased the risk of HTN post-HCT (RR: 1.6; 95% CI, 1.1-2.5), 302 
but only within the first 2 years, suggesting this may revert once medications are 303 
stopped.  304 
 305 
Screening and preventive recommendations  306 
The USPSTF recommends BP assessment every 3 to 5 years in adults aged 18-307 
39 years with normal BP (<130/85 mm Hg) who do not have other risk factors 308 
and annually LQDGXOWVDJHG\HDUVDQGIRUWKRVHZKRDUHDWLQFUHDVHd risk for 309 
high BP. In children, the NHLBI recommends BP assessment yearly after the age 310 
of 3 years, interpreted for age, sex, and height. Current guidelines for HCT 311 
recipients recommend at least annual BP assessment in children and BP 312 
assessment every other year in adults [14, 15]. We recommend BP assessment 313 
for HCT recipients at every clinic visit (at least yearly). The JNC 8 report 314 
recommends initiating pharmacologic treatment for BP of  mmHg in 315 
SHUVRQV 60 years of age (to a BP goal of <150/<90 mmHg) and for BP of 316 
LQSHUVRQV30-59 years of age (to a BP goal of <140/<90) [58]. In the 317 
absence of HCT-specific evidence, these goals can be used to guide 318 
management of HCT recipients, but other factors such as end organ compromise 319 
(cardiac or renal failure) and therapy with calcineurin inhibitors also need to be 320 
taken into account.   321 
 322 
Insulin resistance/diabetes mellitus 323 
DM, which affects almost 10% of the adult population worldwide, is characterized 324 
by hyperglycemia resulting from defects in insulin secretion, insulin action, or 325 
both. The chronic hyperglycemia of DM is associated with long-term damage, 326 
dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, 327 
heart, and blood vessels. The American Diabetes Association (ADA) defines DM 328 
as a IDVWLQJSODVPDJOXFRVH mg/dl (mmol/L), a 2±hour plasma glucose 329 
 mg/dl (11.1 mmol/L), or a hemoglobin A1C (HbA1C)  [62]. Impaired 330 
fasting glucose (IFG, fasting glucose 100-126 mg/dL (5.6-7 mmol/L)) or DM are 331 
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used in most definitions of MetS (Table 1). The treatment of DM may reduce the 332 
progression of microvascular and cardiovascular disease [63-66]. Although 333 
randomized trials have failed to demonstrate an unequivocal benefit, the 334 
identification of patients by screening allows for earlier intervention with potential 335 
reduction in complications [67, 68].  336 
  337 
While hyperglycemia and impaired glucose tolerance (IGT) are well-recognized 338 
complications of cancer and GVHD treatment (corticosteroids), data regarding 339 
the long-term risk of DM in HCT survivors are limited [69]. In the BMTSS, both 340 
allo-HCT (OR, 3.65; 95% CI, 1.82-7.32) and auto-HCT (OR: 2.03; 95% CI, 0.98-341 
4.21) recipients were more likely to report DM than sibling donors [59]. The 342 
incidence of post-HCT DM was 30% among 1-year allo-HCT recipients in both 343 
adult and pediatric populations [61]. In this study, exposure to high-dose 344 
corticosteroids (cumulative prednisone dose of > 0.25 mg/kg/day) increased the 345 
likelihood of developing DM (RR, 3.6; 95% CI, 1.7-7.5) and for having persistent 346 
DM at 2 years post-HCT (RR, 4.1; 95% CI, 1.0-18.2). While data regarding the 347 
incidence of IR in survivors of adult HCT are lacking, the incidence of IR for 348 
pediatric HCT survivors has been estimated to be 10-52% in single center 349 
studies [70-73]. These reports suggest an increased risk for IR/DM in survivors of 350 
both allo- and auto-HCT compared to patients treated with chemotherapy alone 351 
or untreated siblings, even when off immunosuppressive treatments. Preliminary 352 
data from a cross sectional study including 151 HCT survivors (76.8% allo-HCT) 353 
and 92 sibling controls found HCT survivors who had received TBI conditioning 354 
to be significantly more likely to have IR than their sibling controls, but there was 355 
no increased risk of IR for those patients who had a history of acute or chronic 356 
GVHD (personal communication, Baker KS). Multiple studies found high-dose 357 
TBI as a risk factor for IR and IGT, in addition to older age and lipodystropic body 358 
type [72-75]. While data have not demonstrated an increased risk of diabetes to 359 
be directly associated with history of GVHD, further study is warranted. 360 
 361 
Screening and preventive recommendations  362 
The most common tests to screen for diabetes are fasting plasma glucose, two-363 
hour plasma glucose during an oral glucose tolerance test, and HbA1C. The 364 
USPSTF recommends screening for abnormal blood glucose (HbA1C, fasting 365 
plasma glucose or oral glucose tolerance test (OGTT)) every 3 years in adults 366 
aged 40-70 years who are overweight or obese. The NHLBI recommends 367 
screening with a fasting glucose every 2 years after the age of 10 years in 368 
overweight children with other risk factors. Current guidelines for HCT recipients 369 
recommend screening for type 2 DM every 3 years in DGXOWVDJHG\HDUV or in 370 
those with sustained higher BP (>135/80 mm Hg) and fasting glucose at least 371 
every 5 years pediatric survivors [14, 15], which should be appropriate for 372 
standard-risk patients. For high-risk patients with ongoing risk factors (including 373 
those on systemic corticosteroids), we recommend screening for abnormal blood 374 
glucose (HbA1C or fasting plasma glucose) 3 months after HCT with repeat 375 
evaluation every 3-6 months. OGTT may be used to evaluate abnormal 376 
screening results.  For patients with IFG, we encourage weight reduction and 377 
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increased physical activity while patients with type 2 DM should implement 378 
lifestyle therapy and pharmacotherapy, if necessary, to achieve near-normal 379 
HbA1C (<7%). 380 
 381 
Coronary heart disease 382 
More people die from cardiovascular disease each year than from any other 383 
cause. Cardiovascular disease is caused by disorders of blood vessels and is 384 
closely related to atherosclerosis, where endothelial lesions occur up to decades 385 
before clinical manifestations [76, 77]. Risk factors for arteriosclerosis in the 386 
general population are well established and include smoking, arterial HTN, 387 
obesity, DM, dyslipidemia, familial history of CHD, physical inactivity, male 388 
gender and elevated C-reactive protein [78].  389 
 390 
Several studies have attempted to assess the incidence of cardiovascular 391 
disease after HCT, with or without a comparison to a control population. A 392 
retrospective multicenter EBMT analysis showed that 3.6% of long-term allo-HCT 393 
survivors transplanted between 1990 and 1995 had a cardiovascular event in at 394 
least one arterial territory observed [79]. The cumulative incidence of a first 395 
cardiovascular event 15 years after HCT was 6% (95% CI, 3%-10%). One study 396 
reported a cumulative incidence of 7.5% for the first cardiovascular event at 15 397 
years post allo-HCT, as compared with 2.3% post auto-HCT [48]. In multivariate 398 
analysis, allo-HCT, in addition to at least 2 of 4 cardiovascular risk factors (HTN, 399 
dyslipidemia, DM, and obesity) was associated with a higher incidence of 400 
cardiovascular events (RR: 12.4; P=.02). In a retrospective cohort study, 2-year 401 
HCT survivors experienced an increased incidence of cardiovascular death 402 
(adjusted incidence rate difference, 3.6 per 1000 person-years (95% CI, 1.7 to 403 
5.5) when compared with the general population [10]. In this study, an increased 404 
cumulative incidence was also found for ischemic heart disease, cardiomyopathy 405 
or heart failure, stroke, vascular diseases, and rhythm disorders and an 406 
increased incidence of related conditions that predispose toward more serious 407 
cardiovascular disease (HTN, renal disease, dyslipidemia, and DM). In another 408 
study, HCT recipients had significantly higher rates of cardiomyopathy 409 
(4.0% vs. 2.6%), stroke (4.8% vs. 3.3%), dyslipidemia (33.9% vs. 22.3%) and DM 410 
(14.3% vs. 11.7%) (P<.05 for all comparisons) than the general population, 411 
though lower rates of ischemic heart disease (6.1% vs. 8.9%; P<.01) [80 ]. In the 412 
BMTSS, survivors of both allo- and auto-HCT were not more likely to report 413 
arterial disease, myocardial infarction or stroke than sibling donors [59]. One 414 
series, which included 42.7% allo-HCT recipients, reported an incremental 415 
increase in 10-year incidence of cardiovascular disease by number of 416 
cardiovascular risk IDFWRUV  QR IDFWRU  RQH ULVN IDFWRU  417 
risk factors), P<.01); the risk was especially high (15.0%) in patients with multiple 418 
risk factors and pre-HCT exposure to anthracyclines or chest radiation [81]. In 419 
the adult population, it is important to acknowledge that an increasing number of 420 
older patients are undergoing allo-HCT with reduced intensity conditioning and 421 
that future studies are needed to assess the incidence of cardiovascular 422 
complications in this population.  423 
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 424 
In children with acute lymphoblastic leukemia, high-dose TBI and cranial 425 
irradiation correlated with multiple adverse cardiovascular factors including 426 
central adiposity, HTN, IR and dyslipidemia [82, 83]. Some studies have 427 
analyzed the correlation with GVHD and either found a correlation [84] or not [48, 428 
85] and if so, more likely with acute than chronic GVHD [79, 81]. 429 
 430 
Screening and preventive recommendations 431 
In the general population, a person's 10-year risk for CHD is determined based 432 
on age, gender, and conventional CHD risk factors such as smoking, HTN, and 433 
dyslipidemia (Framingham risk score, http://cvdrisk.nhlbi.nih.gov)) [86]. Overall, 434 
the benefits of screening with resting or exercise electrocardiography (ECG) or 435 
for non-traditional risk factors, including coronary artery calcification on electron-436 
beam computerized tomography (EBCT), have not been clearly demonstrated to 437 
outweigh harms. The USPSTF recommends against screening with ECG in 438 
asymptomatic adults with low risk for CHD and concludes that there is insufficient 439 
evidence to assess the balance of benefits and harms of screening with resting 440 
or exercise ECG in asymptomatic adults at intermediate- or high-risk for CHD 441 
events. Similarly, the USPSTF finds insufficient evidence to assess the balance 442 
of benefits and harms of using non-traditional risk factors to screen asymptomatic 443 
men and women with no history of CHD to prevent CHD events. Current 444 
guidelines for HCT recipients do not provide specific screening recommendations 445 
for coronary heart disease [14]. Decisions about screening in adults at increased 446 
risk should be made on a case-by-case basis and after careful discussion with 447 
the patient about the risks and benefits of screening. Although little data are 448 
available about specific interventions in the HCT populations, we recommend a 449 
similar approach.  450 
 451 
Ischemic Stroke 452 
Stroke is the fourth leading cause of death in the United States, whereas globally 453 
it is the second most common cause of mortality and the third most common 454 
cause of disability [87, 88]. Globally, stroke incidence from ischemia is 68% and 455 
32% from hemorrhagic stroke (intracerebral and subarachnoid combined) [89]. 456 
Pediatric stroke is a top ten cause of death in children, occurring at 11 per 457 
100,000 children per year, with acute ischemic stroke accounting for half of all 458 
cases [90-92].  459 
The cumulative incidence of stroke after adult HCT has been reported in single 460 
center series to be 1-5% at a median of 4-10 years following HCT [10, 48, 51, 82, 461 
93]. In one study of 3833 HCT survivors of 1 year (71.3% allo-HCT), the 462 
prevalence of stroke at a median of 10.8 years since HCT was slightly higher 463 
than in a matched general population sample (4.8% vs 3.3%) [51]. Reported risk 464 
factors for stroke include hyperlipidemia, suboptimal physical activity, HTN 465 
treatment before HCT, BMI   NJP2 at HCT, and recurrence of the original 466 
disease [10, 51, 54]. The risk of stroke did not differ statistically between auto- or 467 
allo-HCT, gender, age at HCT, TBI dose, smoking history, donor type, stem cell 468 
source, fruit or vegetable intake, and prior cranial radiation [10, 51, 54, 59]. A 469 
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history of chronic GVHD was associated with an increased risk of stroke among 470 
-year HCT survivors (OR, 2.0; 95% CI, 1.1-3.6) in one study [51], while it was 471 
not statistically associated with risk of stroke in the other studies. Although 472 
ischemic stroke is an indication for HCT in sickle cell disease (SCD), reports 473 
indicate that there is no increased risk post-HCT in this population.  In one report 474 
of pediatric SCD patients, 2 had TIAs after allo-HCT but not stroke [94]. Similarly, 475 
another study of pediatric SCD matched related allo-HCT patients did not report 476 
stroke in those with successful engraftment [95]. Adult SCD may have a higher 477 
risk of stroke and allo-HCT studies in the adult population are ongoing.  478 
  479 
While the reported incidence of stroke in HCT survivors is low, it may be under 480 
recognized due to under reporting. Central nervous system complications ± such 481 
as stroke, posterior reversible encephalopathy syndrome (PRES) and seizures - 482 
also occur frequently in the early post-HCT follow-up with significant impact on 483 
patient survival [96]. Beside the well-known PRES, calcineurin inhibitors may 484 
cause a reversible cerebral vasoconstriction syndrome that can progress to 485 
cerebral infarction [97]. Furthermore neurovascular complication ± including 486 
stroke and transient ischemic attacks (TIA) ± occur commonly upon initial 487 
presentation of thrombotic microangiopathies presentation and cryptogenic 488 
stroke may develop before the onset of alarming hematologic abnormalities [98, 489 
99]. 490 
 491 
Screening and preventive recommendations  492 
The risk of a first stroke can be assessed by a global risk assessment tool such 493 
as the American Heart Association/American College of Cardiology 494 
Cardiovascular Risk Calculation online tool for adults  495 
(http://my.americanheart.org/cvriskcalculator), which has also been endorsed by 496 
the American Academy of Neurology [100]. The USPSTF recommends against 497 
screening for asymptomatic carotid artery stenosis in the general adult 498 
population. Preventive practice includes performing moderate to vigorous aerobic 499 
physical activity for at least 40 minutes 3-4 times a week, statin therapy 500 
according to 10 year calculated cardiovascular risk, implementation of a 501 
Mediterranean diet, HTN therapy, and weight loss in overweight and obese 502 
patients. Current guidelines for HCT recipients do not provide specific screening 503 
recommendations for stroke [14]. In the absence of HCT-specific evidence, these 504 
goals represent appropriate guidelines for HCT recipients. 505 
 506 
Recommendations for screening and preventive practices 507 
While evidence demonstrating the benefits of screening and preventive practices 508 
in HCT survivors is lacking, this review of MetS and cardiovascular disease 509 
emphasizes the high incidence of cardiovascular risk factors and the related 510 
morbidity and mortality experienced by HCT recipients. Based on this data, we 511 
present published guidelines for general population and HCT survivors as well as 512 
consensus recommendations on the screening (Table 2) and preventive 513 
practices (Tables 3) for MetS and cardiovascular disease. HCT survivors with no 514 
identifiable risk factors should be counseled to have a healthy lifestyle and to 515 
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follow the well-established screening recommendations for the healthy 516 
population. However, high-risk patients with ongoing risk factors should be more 517 
closely monitored.   518 
Although not addressed formally in this manuscript, endocrine abnormalities, 519 
such as male hypogonadism, premature menopause, and hypothyroidism can 520 
occur following HCT and may contribute to MetS cardiovascular risk. Health care 521 
providers should be aware of these risks and evaluate for these conditions in 522 
HCT survivors, especially in the presence of MetS or those with risk factors. 523 
 524 
A number of online tools are available to help providers assess risk in patients. In 525 
addition to the Framingham risk score (http://cvdrisk.nhlbi.nih.gov), the AHA 526 
released a mobile application in 2013 (http://tools.acc.org/ASCVD-Risk-527 
Estimator) to estimate 10-year and lifetime risks for atherosclerotic 528 
cardiovascular disease in healthy subjects considering age, ethnicity, gender, 529 
systolic BP, history of smoking and DM, total and HDL cholesterol. However, it is 530 
important to acknowledge that these tools have not been validated in HCT 531 
survivors and thus potentially underestimate risk in this population. 532 
 533 
Conclusion 534 
We provide a consensus recommendations for screening and preventive 535 
measures for MetS and cardiovascular disease in recipients of HCT. Such effort 536 
by the CIBMTR and EBMT Late Effects Working Groups is intended to raise 537 
awareness of the cardiovascular risk in HCT survivors and lead to practices that 538 
will decrease related mortality. This document does not discuss strategies to 539 
achieve these practices (e.g. survivorship clinics, rehabilitation or exercise 540 
programs) given the differences in health care environments between different 541 
countries, but efforts to facilitate such strategies to be developed at the local or 542 
national level are needed. 543 
  544 
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